Our Take
Pharma is buying prime time at the World Cup precisely when the FDA is hunting for enforcement wins—a timing mismatch that could turn a $50M ad spend into a regulatory liability.
Why it matters
The US is the only major market where direct-to-consumer prescription drug advertising is legal. With six billion viewers and Trump administration pressure on the FDA to crack down on misleading claims, World Cup spots will face post-air scrutiny that traditional broadcasts don't.
Do this week
Compliance teams: audit all World Cup spot copy against FDA enforcement patterns (off-label claims, superiority language) before air dates, as warning letters issued within weeks of broadcast amplify reputational damage.
Sanofi and Amgen sign host-city deals; BMS launches branded campaign
Sanofi has partnered with Boston 26, the official World Cup host initiative for the city. The company operates its largest US facility in Massachusetts—a 900,000-square-foot campus employing 2,500 workers, with approximately 5,000 total staff across the state in manufacturing, R&D, and corporate operations. Amgen has similarly partnered with the Los Angeles Sports & Entertainment Commission, named as the official biotech partner and host city supporter. The company is investing in outdoor space enhancement, youth football clinics, preventative health resources, and local nonprofits.
Bristol Myers Squibb is launching its "Won't Lose" campaign ahead of the tournament, featuring narration from US Women's World Cup winner Ali Krieger. The initiative avoids marketing specific drugs or disease states, instead aligning athlete and scientist commitments.
Commercial interest is substantial. Upper-tier sponsorship packages for English-language broadcaster Fox could fetch up to $50 million (per ADWEEK), making World Cup slots among the highest-priced media buys available.
FDA enforcement pressure collides with high-visibility advertising
The US permits direct-to-consumer prescription drug advertising—a policy unique among major economies outside New Zealand. This has created a multibillion-dollar market for TV, radio, and billboard placement. But regulatory momentum has shifted sharply.
In September 2025, President Trump tasked the FDA with clamping down on misleading pharmaceutical ads. The directive followed a controversial telehealth commercial during the Super Bowl. Shortly after, then-FDA commissioner Martin Makary called direct-to-consumer pharmaceutical advertising a "public health crisis" in the US, citing lax agency enforcement.
According to a partner at a US law firm cited in reporting, World Cup placements will receive greater post-air scrutiny from both the FDA and Federal Trade Commission. The most frequent enforcement problems involve off-label efficacy claims or superiority language that is suggested but not explicitly stated. A warning letter issued weeks after broadcast can amplify reputational damage far beyond the original ad spend.
The regulatory timing risk is real
Host-city partnerships like Sanofi's and Amgen's focus on community investment and life sciences ecosystem visibility—lower-risk positioning that avoids direct drug claims. BMS's campaign similarly sidesteps product claims entirely.
But any pharma company running direct-to-consumer spots during the tournament should expect heightened scrutiny. The combination of record viewership (FIFA projects six billion viewers, nearly three-quarters of the global population), Trump administration pressure on FDA enforcement, and the agency's public acknowledgment of a "crisis" in ad compliance creates an unusual window of vulnerability.
For companies proceeding with paid spots, compliance review must go deeper than standard broadcast standards. Off-label language, comparative superiority claims embedded in imagery or voice-over inflection, and disease-state framing all carry higher enforcement risk in this environment. The reputational cost of a warning letter or enforcement action can dwarf even a $50 million ad buy.